CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2019--
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on May 2, 2019 at
8:30 a.m. ET to discuss first quarter 2019 results and provide a general
business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
3368968. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning
approximately two hours after the event and will be archived for
approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres’ SER-287 program has obtained Orphan Drug
designation from the U.S. Food and Drug Administration and is being
evaluated in a Phase 2b study in patients with active mild-to-moderate
ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough
Therapy and Orphan Drug designations from the FDA and is in Phase 3
development for recurrent C. difficile infection. Seres is also
developing SER-401 in a Phase 1b study in patients with metastatic
melanoma. For more information, please visit www.serestherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005615/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi,
Ph.D., Seres Therapeutics
Vice President of Investor Relations and
Corporate Communications
ctanzi@serestherapeutics.com